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Abstract
Background: We present a systematic review and meta-analysis of the available clinical trials
concerning the usefulness of aripiprazole in the treatment of the psychotic symptoms in bipolar
disorder.
Methods: A systematic MEDLINE and repository search concerning clinical trials for aripiprazole
in bipolar disorder was conducted.
Results: The meta-analysis of four randomised controlled trials (RCTs) on acute mania suggests
that the effect size of aripiprazole versus placebo was equal to 0.14 but a more reliable and accurate
estimation is 0.18 for the total Positive and Negative Syndrome Scale (PANSS) score. The effect
was higher for the PANSS-positive subscale (0.28), PANSS-hostility subscale (0.24) and PANSS-
cognitive subscale (0.20), and lower for the PANSS-negative subscale (0.12). No data on the
depressive phase of bipolar illness exist, while there are some data in favour of aripiprazole
concerning the maintenance phase, where at week 26 all except the total PANSS score showed a
significant superiority of aripiprazole over placebo (d = 0.28 for positive, d = 0.38 for the cognitive
and d = 0.71 for the hostility subscales) and at week 100 the results were similar (d = 0.42, 0.63
and 0.48, respectively).
Conclusion: The data analysed for the current study support the usefulness of aripiprazole against
psychotic symptoms during the acute manic and maintenance phases of bipolar illness.
Background
The treatment of bipolar disorder (BD) is difficult since
the illness itself is complex [1-7]. In the BD clinical pic-
ture, psychotic features are a very frequent manifestation
although they are not considered to constitute a core fea-
ture of the disorder. Delusions are relatively more com-
mon than hallucinations. However, it is reported that
unipolar-depressed patients who later 'convert' to BD over
time, as well as bipolar depressives, manifest more fre-
quently psychotic features and pathological (psychotic)
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has been suggested (but not proven) that those patients
with a history of psychotic symptoms suffer from a greater
impairment regarding the neuropsychological perform-
ance especially concerning verbal memory and executive
function [10,11].
Psychotic features include delusions and hallucinations
and both can be mood congruent or non-congruent
depending on their content. Mood congruent psychotic
features include those entirely consistent with the thought
content (either manic or depressive) while mood incon-
gruent features are largely unrelated to thought content.
Overexaggerated thoughts of guilt, sin, worthlessness,
poverty and somatic health, or on the contrary thoughts
of exceptional mental and physical fitness or special tal-
ents, wealth, some kind of grandiose identity or impor-
tance are mood congruent delusions, and even
persecutory ideas or ideas of reference when in accord
with the thought content can be considered to be mood
congruent. Non-congruent delusions include nihilistic
delusions (Cotard delusion or Cotard syndrome, negation
delusion), bizarre delusions and sometimes the delusions
can be so excessive that the identity itself changes. Psy-
chotic symptoms have a profound effect on insight espe-
cially in depressive episodes which otherwise are
characterised by a fair degree of insight. Psychotic features
and the lack of insight might lead to the refusal of any
treatment and to the need for an involuntary admission to
a hospital.
Only during the last few years have antipsychotics and
especially atypicals or second-generation antipsychotics
(SGAs) gained a position in the treatment of BD [12,13].
Their efficacy against acute mania is reported to be inde-
pendent of sedation or of their effect on psychotic symp-
toms. Olanzapine, risperidone, quetiapine, ziprasidone
and aripiprazole are approved for the treatment of acute
mania, quetiapine and the olanzapine-fluoxetine combi-
nation are approved for the treatment of acute bipolar
depression, and olanzapine, quetiapine and aripiprazole
are approved for maintenance phase treatment.
Aripiprazole (7-(4-[4-(2,3-dichlorophenyl)-1-piperazi-
nyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-
14597), is a derivative of the dopamine autoreceptor ago-
nist 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)-
2(1H)-quinolinone (OPC-4392) [14,15], was developed
by Otsuka in Japan and was first approved by the US Food
and Drug Administration (FDA) in 2002 for the treatment
of schizophrenia.
Although psychotic symptoms are common in bipolar
patients, not all randomised controlled trials (RCTs)
include their assessment and up to now there has been no
review or meta-analysis on the efficacy of agents approved
for the treatment of BD on these specific symptoms. The
aim of the current review and meta-analysis was to focus
on outcome measures of randomised controlled trial test-
ing the efficacy of aripiprazole against psychotic symp-
toms in bipolar disorder. To the best of our knowledge no
such analysis exists in the literature to date, and the
reviews available [16-25] either do not include all the tri-
als that have been conducted so far or do not focus on psy-
chotic symptoms.
Methods
Search criteria
The first step of the search included a keyword search of
Medline and the internet via Google with the words 'arip-
iprazole' and 'bipolar'.
The second step included search of the BMS site http://
www.bms.com/clinical_trials/ as well as several relevant
online repositories including http://clinicaltrials.gov,
http://www.clinicalstudyresults.org and http://
www.cochrane.org. The third step included scanning of
the reference lists of various review and meta-analysis
papers [21-28].
Types of studies
The studies selected were RCTs with placebo or a compa-
rator.
Data extraction
All data were extracted by the same author (KNF) from the
full published paper or the clinical study report synopsis.
In some cases some of the data were extracted or calcu-
lated from published meta-analysis or reviews.
Meta-analysis method
The following indices were calculated. Effect size (Cohen
d) was calculated as the mean change divided by the
standard deviation of the scale. It represents the difference
between two groups in the amount of change.
Pooled standard deviation (SDp) was calculated by the
following function:
Where Sp is the pooled standard deviation, ni is the sample
size of the ith sample, si is the standard deviation of the ith
sample, and k is the number of samples being combined.
The Q test for testing the homogeneity of studies was com-
puted by summing the squared deviations of each study's
effect estimate from the overall effect estimate, weighting
S
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was calculated only for the Young Mania Rating Scale
(YMRS) and for placebo-controlled RCTs concerning the
differential d versus placebo and for all studies concerning
the absolute effect of aripiprazole. Not rejecting the
homogeneity hypothesis leads to a fixed effects model
because it is assumed that the estimated effect sizes only
differ by sampling error, while the rejection of the homo-
geneity assumption leads to a random effects model that
includes both intrastudy and interstudy variability.
The I2 index measures the extent of true heterogeneity, and
was calculated by dividing the difference between the
result of the Q test and its degrees of freedom (k-1) by the
Q value itself and multiplying by 100. This index can be
interpreted as the percentage of the total variability in a set
of effect sizes due to true heterogeneity, that is, to inter-
study variability.
The Hunter-Schmidt meta-analysis software was used for
the correction of the effect sizes (d) for sampling error and
measurement error [29] concerning only the effect size
which calibrated the difference between two groups in the
amount of change (aripiprazole vs placebo).
Acute mania/mixed episodes
Six trials assessed the efficacy of aripiprazole against acute
manic/mixed episodes. Theses were CN138-009 [30],
CN138-074 or NCT00036101 [31], CN138-135 or
NCT00095511 [27], CN138-162 or NCT00097266 [32],
CN138-007 which was negative and not published [33],
CN138008 [34] and CN138-077 or NCT00046384,
which did not produce any results due to the small
number of patients recruited. Two of them (CN138-007
and CN138-077/NCT00046384) included a fixed dosage
while the others included a flexible dosage design. Rapid
cycling patients were excluded from CN138-135/
NCT00095511. CN138-077/NCT00046384 did not pro-
duce any results due to the small number of patients
recruited (29 in the aripiprazole arm and 27 in the pla-
cebo arm). Its design included also a fixed dosage, and it
was prematurely closed because it was expected to pro-
duce negative results similar to CN138-007. All used
YMRS as the primary outcome measure. Data on Positive
and Negative Syndrome Scale (PANSS) is not reported by
CN138009 and CN138007, while data for PANSS total
only and some but not all subscales are reported by
CN138074 and CN138135.
The details of these studies (randomised patients, efficacy
and safety sample, publications and results) are shown in
Table 1. The baseline scores for all outcome scales are
shown in Table 2. The similarity of baseline scores across
trials and the similar pooled mean justified the pooling of
all data concerning each arm across studies irrespective
whether the specific study had a placebo or a comparator
arm or not. The dropout rates are shown in Table 3. The
changes in the PANSS scales scores are shown in Table 4.
The effect sizes (d) are shown in Table 5. The side effects
frequency is shown in Table 6. The forest plot is shown in
Figure 1.
After including only the RCTs reporting PANSS data
(CN138009 and CN138007 were excluded), in total
1,640 patients were randomised and the total efficacy
sample included 1,534 patients (613 in the aripiprazole
group, 447 the placebo group and 474 in active control
groups) while the safety sample included 1,574 (631 in
the aripiprazole group, 450 in the placebo group and 493
in active control groups) (Table 1). The pooled dropout
rate for the RCTs which reported PANSS data was 36.22%
for aripiprazole, 43.62% for placebo and 42.83% for com-
parator at week 3, climbing to 56.81% and 62.87% at
week 12 for aripiprazole and comparator, respectively.
The dropout rates are shown in detail in Table 3.
The pooled d value for total PANSS score for all placebo-
controlled studies with a fixed model was equal to 0.191
(95% CI 0.08 to 0.304), with a Q value equal to 5.024
(degrees of freedom (df) = 3; P = 0.170), which does not
reject the homogeneity hypothesis. The I2 is equal to
40.283, which means that less than half of observed vari-
ability in the effect sizes across studies is due to true heter-
ogeneity. However a random model gives similar results
(d = 0.194; 95% CI 0.05 to 0.34). The Hunter-Schmidt
method reports d = 0.18 (95% CI 0.176 to 0.184) after
correcting for sampling and measurement error (Table 5).
Acute bipolar depression
There were two 8-week placebo controlled RCTs (CN138-
096/NCT00080314 and CN138-146/NCT00094432)
concerning the use of aripiprazole in acute bipolar depres-
sion, and were both negative at study endpoint [35].
These included non-psychotic bipolar depressives and
thus do not report data on psychotic symptoms.
Maintenance treatment
There was one placebo-controlled RCT (CN138-010/
NCT00036348) that studied aripiprazole in the mainte-
nance phase [36]. Patients were stabilised with 15 to 30
mg of aripiprazole for 6 to 18 weeks and then randomised
to a 1:1 ratio to aripiprazole or placebo for an additional
26 weeks. The baseline mean YMRS score was 2.5 ± 2.8 for
the aripiprazole group and 2.1 ± 2.3 for the placebo
group. The Montgomery-Åsberg Depression Rating Scale
(MADRS) baseline scores were 3.9 ± 3.5 and 4.5 ± 4.2,
respectively. Only anticholinergics and lorazepam were
allowed as concomitant medication. During the 26 weeks
71.1% of patients under placebo and 71.4% of patients
under aripiprazole received at least one concomitant med-Page 3 of 10
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for a mood episode. From a total of 633 patients initially
screened and 206 of them who completed the stabilisa-
tion phase, 161 were randomised (83 to placebo and 78
to aripiprazole). A total of 39 patients (50%) under arip-
iprazole and 28 (34%) under placebo completed the 26
weeks of the trial. The mean aripiprazole daily dosage at
the end of 26 weeks was 24.3 mg. The time to relapse was
significantly longer for aripiprazole (P = 0.02) and the
hazard ratio (HR) was 0.52 (95% CI 0.30 to 0.91).
For the PANSS total score, a numerical trend favoured
aripiprazole over placebo at any time point. At week 26,
the changes (mean ± SD) in PANSS total scores were 5.2 ±
14.57 for aripiprazole and 9.1 ± 13.24 for placebo (P =
0.077), for the PANSS cognitive subscale score were for
aripiprazole, 0.8 ± 4.55; placebo, 2.5 ± 4.41; P = 0.014)
and for the PANSS hostility subscale score for aripipra-
zole, 0.8 ± 2.73; placebo, 1.8 ± 2.65; P = 0.032). All except
the total PANSS score showed a significant superiority of
aripiprazole over placebo, with d = 0.28, 0.38 and 0.71,
respectively.
The adverse events reported by aripiprazole-treated
patients at an incidence ≥ 5% and twice the incidence of
placebo during the maintenance phase were tremor
(9.1%), acathisia (6.5%), vaginitis (6.4%), and pain
extremity (5.2%). One aripiprazole-treated patient and
one placebo-treated patient attempted suicide in the stabi-
lisation and maintenance phases, respectively. There were
no significant differences concerning the QTc, while arip-
iprazole-treated patients showed a significant drop in pro-
lactin levels. Concerning weight gain, 13% of
aripiprazole-treated patients put > 7% of weight in com-
parison to none in the placebo group.
This same trial (CN138-010/NCT00036348) was
expanded and included also a 74-week placebo controlled
extension phase [37], which included 66 of the 67
patients who completed the 26-week period. Unfortu-
nately only 12 of them (5 in the placebo group and 7 in
the aripiprazole group) completed the 74-week treatment
period. The reasons for this high discontinuation rate var-
ied and included lack of efficacy, side effects (very low per-
centage) and most importantly the very design and
structure of the study (the study was closed by the sponsor
when the prespecified number of relapses had been
attained). Because of this and because detailed descriptive
data are not reported, arriving at conclusions is very diffi-
cult. The mean dosage of aripiprazole at the end of the 74-
week period was 23.6 mg daily. It is reported that 29 out
of the 66 patients relapsed (16 out of the 39 in the arip-
iprazole group (41%), and 13 out of the 27 in the placebo
group (48.1%)). The only difference concerned manic
relapses (nine in the placebo group and six in the aripipra-
zole group). Again the YMRS score significantly differed
between groups. The adverse events had a similar rate to
the 26-week period.
In both the above reports the median survival time for the
aripiprazole group was not evaluable, while the median
survival time for placebo was 118 to 203 days depending
on the clinical subpopulation. At week 100, the changes
(mean ± SD) in PANSS total scores were 7.9 ± 10.61 for
aripiprazole and 11.8 ± 8.31 for placebo (P = 0.10), for
the PANSS cognitive subscale score were for aripiprazole,
1.5 ± 3.12; placebo, 3.3 ± 2.59 (P = 0.01) and for the
Table 1: List of acute mania trials of aripiprazole and their characteristics
Trial Publication Duration COMP PLC Randomised, N Efficacy sample, N Safety sample, N Results
AR COMP PLC AR COMP PLC AR COMP PLC
CN138-009 Keck et al., 2003 [27] 3 weeks No Yes 127 Agent > PLC
CN138-074/
NCT00036101
Sachs et al., 2006 [28] 3 weeks No Yes 137 135 136 132 136 133 Agent > PLC
CN138-135/
NCT00095511
Keck et al., 2009 [29] 12 weeks Li Yes 155 160 165 154 155 163 154 159 164 Agent = comparator > PLC
CN138-162/
NCT00097266
Young et al., 2009 [30] 12 weeks Hal Yes 167 165 153 152 161 152 166 165 153 Agent = comparator > PLC
CN138-007 Unpublished 3 weeks No Yes 267 134 267 - 134 - 267 - 134 - Agent = PLC
CN138-077/
NCT00046384
Unpublished 3 weeks No Yes 29 27 No results
CN138008 Vieta et al., 2005 [32] 12 weeks Hal No 175 172 171 158 175 169 Agent > comparator
All RCTs
Total by groups 1,060 497 746 1,005 474 704 1,025 493 711
Total 2,303 2,183 2,229
Only RCTs with 
PANSS data
Total by groups 663 497 480 613 474 447 631 493 450
Total 1,640 1,534 1,574
Dash indicates missing data. AR = aripiprazole; COMP = comparator; PANSS = Positive and Negative Syndrome Scale; PLC = placebo; 
RCT = randomised controlled trial.Page 4 of 10
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placebo, 2.3 ± 2.07 (P = 0.03). Again all except the total
PANSS score showed a significant superiority of aripipra-
zole over placebo, with d = 0.42, 0.63 and 0.48, respec-
tively [38].
The expansion of the 135-008 trial [34] to a further 14
weeks failed to provide any results because of a high drop-
out rate, while the extension of the CN138-135/
NCT00095511 trial [27] for an additional 40 weeks (52
weeks in total) comparing aripiprazole to lithium without
a placebo arm suggested aripiprazole equal to lithium in
the maintenance against manic episodes. No PANSS data
are reported concerning this extension phase.
Discussion
The meta-analysis of the four trials that investigated the
efficacy of aripiprazole on psychotic symptoms (assessed
by the PANSS) during acute manic/mixed episodes sug-
gests that the effect size versus placebo was equal to 0.14,
but a more reliable and accurate estimation is 0.18 for the
total PANSS score. The effect was higher for the PANSS
positive subscale (0.28), PANSS hostility subscale (0.24)
and PANSS cognitive subscale (0.20), and lower for the
PANSS negative (0.12). The majority of these trials
included patients with moderate to severe manic epi-
sodes, some of whom also had psychotic symptoms. No
data on the depressive phase of bipolar illness exist, while
there are some data in favour of aripiprazole concerning
the maintenance phase, where at week 26 all except the
total PANSS score showed a significant superiority of arip-
iprazole over placebo (d = 0.28 for positive, d = 0.38 for
the cognitive and d = 0.71 for the hostility subscales) and
at week 100 the results were similar (d = 0.42, 0.63 and
0.48, respectively). It is important to note that the efficacy
for both haloperidol and lithium is similar to aripiprazole
in the psychotic symptoms of BD. This could seem odd
concerning lithium, which is not considered to possess
antipsychotic efficacy (although it is recommended as
augmentation strategy in refractory patients with schizo-
phrenia). However the literature suggests that in essence
lithium might exert a state-dependent effect on second
messenger systems that is antidopaminergic-like during
manic episodes (when dopaminergic activity seems to be
elevated). Thus this state-dependent antidopaminergic
activity could be responsible for this antipsychotic action
[39,40].
Table 2: The baseline scale scores in aripiprazole randomised controlled trials (RCTs) of acute mania.
Trial PANSS-total PANSS-positive PANSS-negative PANSS-cognitive PANSS-hostility N (efficacy sample)
Aripiprazole
CN138-009 - - - - - 125
CN138-074 61.8 ± 16.7 - - - - 136
CN138-135 62.0 ± 13.7 - - 15.2 ± 3.4 10.1 ± 3.4 154
CN138-162 54.8 ± 10.3 16.0 ± 3.9 9.6 ± 2.6 14.7 ± 3.9 9.7 ± 2.6 152
CN138-007 - - - - - 267 -
CN138008 - - - - - 171
Pooled mean 59.5 16.0 9.6 14.9 9.9 1,005
Pooled SD 13.7 3.9 2.6 3.6 3.0
Placebo
CN138-009 - - - - - 123
CN138-074 62.5 ± 16.5 - - - - 132
CN138-135 63.9 ± 13.1 - - 15.3 ± 3.6 10.4 ± 3.6 163
CN138-162 54.4 ± 10.3 16.4 ± 4.9 9.4 ± 2.5 14.9 ± 3.7 9.7 ± 2.5 152
CN138-007 - - - - - 134 -
CN138008
Pooled mean 60.3 16.4 9.4 15.1 10.0 704
Pooled SD 13.4 4.9 2.5 3.6 3.1
Comparator
CN138-009
CN138-074
CN138-135 63.2 ± 12.9 - - 15.6 ± 3.5 10.5 ± 3.5 155
CN138-162 54.1 ± 10.3 16.1 ± 3.9 9.5 ± 2.5 14.6 ± 3.9 9.4 ± 2.5 161
CN138-007
CN138008 - - - - - 158
Pooled mean 58.6 16.1 9.5 15.1 9.9 474
Pooled SD 11.6 3.9 2.5 3.7 3.0
Dash indicates missing data.
aCalculated from Suppes et al. 2008 [21]; data were not used for the calculation of the pooled mean because there is no data on the change.
PANSS = Positive and Negative Syndrome Scale.Page 5 of 10
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Table 3: Dropout in aripiprazole randomised controlled trials (RCTs) for acute mania; data concern numbers of patients while the last row concerns rates
Trial Aripiprazole Placebo Comparator
3 weeks 12 weeks 3 weeks 3 weeks 12 weeks
Total LE AE CW Total LE AE CW Total LE AE CW Total LE AE CW Total LE AE CW
CN138-009 76 23 11 25 104 53 13 38
CN138-074 58 12 12 34 64 28 10 26
CN138-135 82 9 23 15 113 12 31 70 87 36 13 10 82 26 21 5 106 26 28 52
CN138-162 41 9 14 18 72 13 24 35 44 14 16 14 44 10 8 26 70 11 18 41
CN138-007
CN138008 41 - 17 - 86 30 32 24 77 - 53 - 122 10 84 28
All RCTs
Dropout (%) 40.38 9.35 10.43 16.23 56.81 11.53 18.24 27.04 52.46 22.98 9.12 15.44 42.83 11.39 17.30 9.81 62.87 9.92 27.43 25.53
Only RCTs with 
PANSS data
Dropout (%) 36.22 6.79 10.77 15.16 56.81 11.53 18.24 27.04 43.62 17.45 8.72 11.19 42.83 11.39 17.30 9.81 62.87 9.92 27.43 25.53
Dash indicates missing data.
AE = adverse events; CW = consent withdrawal or other; LE = lack of efficacy; PANSS = Positive and Negative Syndrome Scale.
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Table 4: Change in Positive and Negative Syndrome Scale (PANSS) scores in acute mania aripiprazole randomised controlled trials (RCTs)
Trial 3 weeks 12 weeks N 
(efficacy sample)
PANSS-total PANSS-positive PANSS-negative PANSS-cognitive PANSS-hostility PANSS-total PANSS-positive PANSS-negative PANSS-cognitive PANSS-hostility
Aripiprazole
CN138-009 - - - - - 125
CN138-074 -10.0 ± 18.2 - - - - 136
CN138-135 -9.5 ± 17.4 - - -2.0 ± 4.6 -2.1 ± 4.6 -10.6 ± 19.4 - - -2.9 ± 5.7 -2.5 ± 4.6 154
CN138-162 -8.2 ± 12.9 -3.8 ± 5.1 -0.4 ± 2.6 -2.4 ± 3.9 -2.3 ± 3.9 -9.8 ± 14.2 -4.9 ± 5.2 -0.2 ± 2.6 -3.2 ± 5.2 -3.0 ± 3.9 152
CN138-007 -2 ± -a - - - - 267 -
CN138-008 - - - - - - - - - - 171
Pooled mean -6.5 -3.8 -0.4 -2.2 -2.2 -10.2 -4.9 -0.2 -3.0 -2.7 1,005
Pooled SD 16.3 5.1 2.6 4.3 4.3 16.9 5.2 2.6 5.5 4.3
Placebo
CN138-009 - - - - - 123
CN138-074 -5.3 ± 17.9 - - - - 132
CN138-135 -4.9 ± 16.7 - - -0.9 ± 4.8 -1.0 ± 3.6 163
CN138-162 -4.7 ± 12.4 -2.4 ± 4.9 -0.1 ± 2.5 -1.5 ± 6.2 -1.2 ± 6.2 152
CN138-007 -2.3 ± -a - - - - 134 -
CN138-008
Pooled mean -4.3 -2.4 -0.1 -1.2 -1.1 704
Pooled SD 15.8 4.9 2.5 5.5 5.0
Comparator
CN138-009
CN138-074
CN138-135 -7 ± 17.7 - - -1.6 ± 4.7 -1.6 ± 3.5 -7.4 ± 18.8 - - -2.0 ± 4.7 -1.8 ± 4.7 155
CN138-162 -8.8 ± 12.8 -4.2 ± 5.1 -0.3 ± 2.6 -2.5 ± 3.9 -2.6 ± 3.9 -11.7 ± 14.1 -5.4 ± 5.1 -0.3 ± 2.6 -3.9 ± 5.1 -3.5 ± 3.9 161
CN138-007
CN138-008 - - - - - - - - - - 158
Pooled mean -7.9 -4.2 -0.3 -2.0 -2.1 -9.6 -5.4 -0.3 -3 -2.7 474
Pooled SD 15.4 5.1 2.6 4.3 3.7 16.6 5.1 2.6 4.9 4.3
Dash indicates missing data.
aNot included in the calculation of the pooled measures because of a different study design (fixed dosage).
Annals of General Psychiatry 2009, 8:27 http://www.annals-general-psychiatry.com/content/8/1/27In comparison to the baseline scores reported in schizo-
phrenia RCTs with aripiprazole, the respective PANSS
scores in bipolar RCTs are significantly lower and this is of
course expected. The PANSS-positive scores in schizophre-
nia RCTs range are around 29, for PANSS-negative they
are around 22 and for PANSS-hostility around 9.5, while
difference from placebo is again larger with 2.63 points
difference in PANSS-positive, 2.31 points for PANSS-neg-
ative and 1.96 for PANSS-hostility [41]. However in these
studies no standard deviations are reported and it is not
possible to derive, thus the real effect sizes can not be cal-
culated [42]. The only comparison that can be made is in
terms of the ratio change to baseline. This ratio is similar
for PANSS-positive (around 10%), but much different
concerning PANSS-negative (10% in schizophrenia vs 3%
in BD) and PANSS-hostility (20% for schizophrenia vs
11% for BD).
These results should be interpreted in light of recent stud-
ies on common genetic findings in schizophrenia and
mood disorders [43-47].
There are several meta-analyses in the literature concern-
ing the efficacy of various agents in the treatment of bipo-
lar illness, but none analyse the effect on psychotic
symptoms [21-28]. These meta-analyses suggest that arip-
iprazole's antimanic effect is specific and not limited to
control of agitation through sedation, but no data on psy-
chotic symptoms are analysed. Additionally, there is a
concern regarding aripiprazole and olanzapine mainte-
nance data because the relevant studies included patients
who were responders specifically to the drug under inves-
tigation during the acute phase.
A few issues concerning the data of the RCTs should be
pointed out however, because they reveal the restrictions
of RCTs, as well as the gaps in our current knowledge and
understanding and treating of bipolar illness. The first
point is that although acute mania is generally considered
one of the 'easier to treat' psychiatric conditions, with only
5% of bipolar patients experiencing chronic mania
(although such a diagnostic condition is not recognised
by the Diagnostic and Statistical Manual, Fourth Edition,
Text Revision (DSM-IV-TR)) [48], in the acute mania RCTs
around half of acutely manic patients were non-respond-
Table 5: Effect sizes for Positive and Negative Syndrome Scale (PANSS) total and subscales
PANSS total PANSS-positive PANSS-negative PANSS-cognitive PANSS-hostility
d 95% CI d 95% CI d 95% CI d 95% CI d 95% CI
Aripiprazole vs placebo
CN138-009 - - - - -
CN138-074 0.26 0.02 to 0.50 - - - -
CN138-135 0.27 0.05 to 0.49 - - 0.23 0.01- to 0.45 0.27 0.05 to 0.49
CN138-162 0.28 0.05 to 0.50 0.28 0.05 to 0.51 0.12 -0.11 to 0.34 0.17 -0.05 to 0.40 0.21 -0.01 to 0.44
CN138-007 -0.02 -0.23 to 0.19 - - - -
CN138-008 - - - - -
Pooled mean 0.14 0.03 to 0.25 0.28 0.05 to 0.51 0.12 -0.11 to 0.34 0.20 0.04 to 0.36 0.24 0.08 to 0.39
Hunter-Schmidt d 0.18 0.176 to 0.184 - - 0.20 - 0.24 -
Comparator vs placebo
CN138-135 0.12 -0.10 to 0.34 - - 0.15 -0.07 to 0.37 0.17 -0.05 to 0.39
CN138-162 0.33 0.10 to 0.55 0.36 0.14 to 0.58 0.08 -0.14 to 0.30 0.19 -0.03 to 0.42 0.27 0.05 to 0.49
Pooled mean 0.23 0.10 to 0.36 0.36 0.14 to 0.58 0.08 -0.14 to 0.30 0.16 0.01 to 0.32 0.23 0.07 to 0.38
Dash indicates missing data.
Table 6: Side effects profile of aripiprazole in comparison to placebo (difference percentage).
Trial Target Overall side effects Anxiety Agitation Acathisia Constipation Headache Hyperprolactinaemia Insomnia Nausea Sedation
CN138-009 Mania 8 1 9 7 5 -6 6 13 15
CN138-074 Mania 6 2 0.4 13.1 6.5 0.2 -7 5.5 9.4
CN138-135 Mania 8 4.3 0.8 9.3 6.8
CN138-162 Mania 0.1 11.4 6.8 1.8 2.1 5.4
CN138008 Mania 11.4 10.9 13.7
CN138-096 Depression 11 2.9 4.7 22.7 -1.5 -1.1 11.5 9.8 1.3
CN138-146 Depression 6 6.5 9.3 18.6 1.6 -2.3 7.7 6.6 1.1
CN138-010 Maintenance 6 -14.5 -10.8 6.6 7.8 -19.3 4.3 -7.2
CN138-134 Mania 8.3 13.2 5.2
Negative results suggest the effect in question was more frequent in the placebo group.Page 8 of 10
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but maybe also refractory. The question whether the dos-
age should be raised is open and pressing. Higher dosages
for all agents might be necessary to be studied. During the
maintenance phase, around three-quarters of patients will
drop out of aripiprazole treatment within the first year in
comparison to almost all the patients under placebo, and
although the difference is significant, it suggests that even
under effective treatment, a significant number patients
tend to relapse although at a lower frequency of episodes.
Finally, the fixed dosage RCT was negative, suggesting that
aripiprazole should be prescribed at an individualised
basis. Similar issues have been recently raised because of
the still unpublished results of the one study of paliperi-
done in acute mania, which also used a fixed dose
approach (the second one utilised a flexible dosage
design) and reported that 6 and 9 mg were not effective
versus placebo while 12 mg was.
Conclusively, the data analysed for the current study sup-
ports the usefulness of aripiprazole against the psychotic
symptoms during the acute manic/mixed and mainte-
nance phases of bipolar illness, however there are specific
issues the clinician should have in mind, such as that the
maintenance effect is proven only in patients with an
index manic episode that responded to aripiprazole dur-
ing the acute phase. Higher and ever-increasing placebo
rates constitute a problem of quality for RCTs today and
limit the generalisability of results [49]. A limitation of
this review is that most of the trials were sponsored by the
pharmaceutical industry and were conducted to gain reg-
ulatory approval for aripiprazole for the treatment of
bipolar disorder. Therefore, the possibility of sponsor bias
induced in favour of their product cannot be excluded,
especially since failed trials were not published and the
available data from them are limited.
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